Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor
Impact Of An Integrated Intervention Program On Adherence To Atorvastatin
1 other identifier
observational
500
1 country
3
Brief Summary
Despite extensive reports of the benefits of statins in reducing serious cardiovascular events such as stroke and heart disease in patients with elevated LDL-cholesterol, patients do not take their medicines regularly as prescribed. Reasons include forgetfulness, lack of understanding of the seriousness of the disease, and fear of side effects. An intervention strategy comprising 3-5 minutes of counseling, emotional support and cost-sharing may be motivational and improve adherence to treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2010
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 25, 2010
CompletedStudy Start
First participant enrolled
March 1, 2010
CompletedFirst Posted
Study publicly available on registry
March 2, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2011
CompletedFebruary 18, 2021
February 1, 2021
1.7 years
February 25, 2010
February 16, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of Days Covered (PDC)
180 days
Secondary Outcomes (4)
Medication Possession Ratio (MPR)
180 days
Persistence-the number of continuous days a patient is supplied with medication using the allowable grace period or gap (30 or 60 days).
180 days
Percent of patients that are at least 80% adherent (PDC>0.8)
180 days
Percent of patients who fill at least one atorvastatin prescription during the period of study
180 days
Study Arms (2)
Control
Intervention Arm
Interventions
Patients do not receive any adherence counseling, or other patient support services
Patients receive 3-5 minutes of adherence counseling, and other patient support services
Eligibility Criteria
* Male and female aged \>21 years * Have received a new or re-fil prescription for atorvastatin at first study visit to Prairie Heart Institute * Signed informed consent
You may qualify if:
- Male and female aged \>21 years
- Have received a new or re-fil prescription for atorvastatin at first study visit to Prairie Heart Institute
- Signed informed consent
You may not qualify if:
- Unwilling to give written informed consent
- Failed statin treatment in the past
- Switched from another statin to atorvastatin because of co-pay program
- Participated in an earlier Market Research study on Impact of cholesterol management behaviors post in-clinic adherence intervention
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Prairie Heart Institute
Springfield, Illinois, 62701, United States
Memorial Medical Center
Springfield, Illinois, 62702, United States
Prairie Diagnostic Center
Springfield, Illinois, 62702, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 25, 2010
First Posted
March 2, 2010
Study Start
March 1, 2010
Primary Completion
November 1, 2011
Study Completion
November 1, 2011
Last Updated
February 18, 2021
Record last verified: 2021-02